About: Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 13 April 2011

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у квітні 2011 (uk) article scientifique publié en 2011 (fr) im April 2011 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 13 April 2011 (en) artículu científicu espublizáu n'abril de 2011 (ast)
publication date	wds:Q61776046-7D2BF256-D75C-4B4B-85E5-A4DC5BECC8B0
publication date	2011-04-13 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q61776046-1B6490F4-3015-46EA-8AF1-DDB529A7DE2B
language of work or name	English
author name string	wds:Q61776046-AB053D95-55C5-4415-8600-CEA695E8672B wds:Q61776046-EE2E3C67-CAD2-41E2-BC49-7F1F33271BF2
author name string	Robert J Harris Richard E Clark
rdfs:label	Cancerous inhibitor of PP2A (nl) Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression (en)
skos:prefLabel	Cancerous inhibitor of PP2A (nl) Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression (en)
name	Cancerous inhibitor of PP2A (nl) Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression (en)
author	wds:Q61776046-06F60788-B143-4198-B006-C8795AC431E2 wds:Q61776046-15B6A731-2806-41DA-A59B-A08EC237B286 wds:Q61776046-21B569C5-22D3-44DF-BE7B-2601B39B63F4 wds:Q61776046-3815ABF5-2973-472D-BEEB-23D46A0770E1
author	Joseph R Slupsky Mhairi Copland Athina Giannoudis Claire M Lucas
title	wds:Q61776046-7BBE5FAC-139B-40B1-90F5-33D38ACD0A56
title	Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression (en)
page(s)	wds:Q61776046-369E2297-46EC-421A-97C4-88DDB83C20FA
page(s)	6660-6668
instance of	wds:Q61776046-DC4F6D4D-8214-434F-941A-E379D7580FBC
instance of	scholarly article
main subject	wds:Q61776046-125B9E9D-5795-49E7-94F0-0FA33A1CFB86 wds:Q61776046-294AA16D-A274-4458-A99B-69838B3D4913
main subject	chronic myeloid leukemia myeloid leukemia
PubMed ID	wds:Q61776046-35F8FDA7-9A02-4083-B0A1-2F2C7995D983
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/21490338
PubMed ID	21490338
published in	wds:Q61776046-AC815C04-EF49-42A9-BC57-D279D4EB2E44
published in	Blood
issue	wds:Q61776046-7A4DA983-845D-4C3D-9CD4-B0F20B98B76A
volume	wds:Q61776046-EB38D19F-1674-4508-AEFC-18C6060612C8
issue	24
volume	117
number of pages	wds:Q61776046-3E4F20A3-0CBD-448C-97BD-59791FF9CDAC
number of pages	9 (xsd:decimal)
DOI	wds:Q61776046-905F81FF-2CFE-4189-AAD3-AD63F6CDFC46
DOI	http://dx.doi.org/10.1182/BLOOD-2010-08-304477
DOI	10.1182/BLOOD-2010-08-304477
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q61776046
is cites work of	MYC oncogene in myeloid neoplasias. Protein phosphatase 2A: a target for anticancer therapy TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets Identifying and validating a combined mRNA and microRNA signature in response to imatinib treatment in a chronic myeloid leukemia cell line Identification of protein interactions involved in cellular signaling The broken "Off" switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients' survival Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias Cyanobacterial Toxins of the Laurentian Great Lakes, Their Toxicological Effects, and Numerical Limits in Drinking Water Selecting the best frontline treatment in chronic myeloid leukemia Overexpression of protein phosphatase 4 correlates with poor prognosis in patients with stage II pancreatic ductal adenocarcinoma Targeting survival pathways in chronic myeloid leukaemia stem cells CIP2A influences survival in colon cancer and is critical for maintaining Myc expression Pushing the limits of targeted therapy in chronic myeloid leukaemia. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells p90/CIP2A mediates breast cancer cell proliferation and apoptosis The Basic Biology of PP2A in Hematologic Cells and Malignancies From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies Autoantibodies to tumor-associated antigens as biomarkers in human hepatocellular carcinoma (HCC). c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia Tissue proteomics of splenic marginal zone lymphoma Regulation of PP2A by Sphingolipid Metabolism and Signaling Label-free quantitative phosphoproteomics with novel pairwise abundance normalization reveals synergistic RAS and CIP2A signaling. Protein phosphatase 2A (PP2A) inhibitor CIP2A indicates resistance to radiotherapy in rectal cancer. Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options. Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells Cellular localization of CIP2A determines its prognostic impact in superficial spreading and nodular melanoma Ethoxysanguinarine Induces Inhibitory Effects and Downregulates CIP2A in Lung Cancer Cells. CIP2A expression and prognostic role in patients with esophageal adenocarcinoma. Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth. Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1. Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients. Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer. Expression of cancerous inhibitor of protein phosphatase 2A in human triple negative breast cancer correlates with tumor survival, invasion and autophagy High expression of CIP2A protein is associated with tumor aggressiveness in stage I-III NSCLC and correlates with poor prognosis. Feedback between E2F1 and CIP2A regulated by human papillomavirus E7 in cervical cancer: implications for prognosis Aberrant activation of CaMKIIγ accelerates chronic myeloid leukemia blast crisis. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins Investigation of PP2A and Its Endogenous Inhibitors in Neuroblastoma Cell Survival and Tumor Growth Ten years of research on the role of BVES/ POPDC1 in human disease: a review Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update Cancerous Inhibitor of PP2A Silencing Inhibits Proliferation and Promotes Apoptosis in Human Multiple Myeloma Cells

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 170 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software